A Phase 2, Open-Label, Single-Arm, Multicenter Study Evaluating the Safety and Antitumor Activity of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90 (HSP90), in Patients With Metastatic Melanoma.

Trial Profile

A Phase 2, Open-Label, Single-Arm, Multicenter Study Evaluating the Safety and Antitumor Activity of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90 (HSP90), in Patients With Metastatic Melanoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca; Infinity Pharmaceuticals; MedImmune
  • Most Recent Events

    • 03 Sep 2008 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 22 Jul 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 19 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top